Turnstone Biologics Corp. Common Stock (TSBX) - Total Liabilities
Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) has total liabilities worth $6.34 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Turnstone Biologics Corp. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Turnstone Biologics Corp. Common Stock's working capital to evaluate short-term liquidity relative to the company's equity base.
Turnstone Biologics Corp. Common Stock Competitors by Total Liabilities
The table below lists competitors of Turnstone Biologics Corp. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
aXichem AB
ST:AXIC-A
|
Sweden | Skr9.69 Million |
|
LDT Inc
KQ:096870
|
Korea | ₩2.45 Billion |
|
Wahana Pronatural
JK:WAPO
|
Indonesia | Rp98.34 Billion |
|
Renew Holdings plc
LSE:RNWH
|
UK | GBX328.01 Million |
|
Moonpig Group PLC
LSE:MOON
|
UK | GBX238.69 Million |
|
Silla Sg Co. Ltd
KQ:025870
|
Korea | ₩33.67 Billion |
|
Northann Corp.
NYSE MKT:NCL
|
USA | $11.43 Million |
|
Euro Menkul Kiymet Yatirim Ortakligi AS
IS:EUYO
|
Turkey | TL5.13 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Turnstone Biologics Corp. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TSBX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Turnstone Biologics Corp. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual total liabilities of Turnstone Biologics Corp. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.67 Million | -38.71% |
| 2023-12-31 | $14.15 Million | -93.46% |
| 2022-12-31 | $216.41 Million | -19.58% |
| 2021-12-31 | $269.10 Million | -- |
About Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.